

11th ESDO MASTERCLASS



Novel Strategies in GI Oncology



19 – 20 NOVEMBER 2027



VENICE, ITALY



11th ESDO MASTERCLASS

NOVEL STRATEGIES IN GI ONCOLOGY



19-20
NOVEMBER 2027



VENICE



LOCAL SCIENTIFIC COMMITTEE



AVIANO

Gustavo **Baldassarre**
Michela **Guardascione**
Fabio **Puglisi**



PADOVA

Sara **Lonardi**



VERONA

Maria **Bencivenga**



UDINE

Giuseppe **Aprile**



EUROPEAN SCIENTIFIC COMMITTEE

President, ESDO

Eric Van Cutsem

University Hospital Gasthuisberg
Leuven, Belgium

Secretary General, ESDO

Thomas Seufferlein

University Hospital Ulm
Ulm, Germany

Introduction

Within the field of GI oncology, the role of a multidisciplinary approach involving medical oncologists, surgeons, radiation oncologists and gastroenterologists is increasingly recognized.

The European Society of Digestive Oncology (ESDO), founded many years ago, has as its mission to provide high-level education across multiple medical disciplines, through webinars and scientific events held in person with leading international experts, together with other educational activities.

The annual ESDO Masterclass is now a well-established scientific event, reaching its twelfth edition this year. This event has never previously been held in Italy, and we believe that bringing it to our country can provide an important scientific contribution to the Italian oncology community, as well as to other related medical disciplines.

Italian and international experts will be present to provide updates on the most relevant advances in targeted therapies and immunotherapy in gastrointestinal and pancreatobiliary cancers. The event will also provide an opportunity to critically discuss some of the still controversial issues in GI oncology.

We believe that opportunities for exchange and discussion such as this, characterized by a multidisciplinary approach and an international and Italian faculty, are extremely valuable, and we hope to see more such initiatives in the coming years.

Preliminary Programme

19th November

16.00-16.10 Welcome from Scientific Committee

Session 1 _____ Recent updates on targeted/immune-therapies in GI tumors

16.10-16.30 Colorectal cancer

16.30-16.50 Gastroesophageal cancer

16.50-17.10 Hepatobiliary tumors

17.10-17.30 Pancreatic cancer

17.30-17.50 Q&A

Session 2 _____ Case-based presentations from ESDO Young Group: what oncologist would like to see and not see!

17.50-18.05 Clinical case of pancreatic cancer

18.05-18.20 Clinical case of cholangiocarcinoma

18.20-18.35 Q&A

18.35-18.50 Sponsored corner “Molecules under development in digestive cancers”

20th November

Session 3_____The spectrum of useful predictive biomarkers in GI Oncology

09.00-09.20	Do TCGA molecular classification and currently validated biomarkers run on parallel tracks in gastric cancer?
09.20-09.40	Biomarker co-expression in gastric cancer and cholangiocarcinoma: state of the art
09.40-10.00	The complex interplay between microbiome and therapeutic response in colorectal cancer
10.00-10.20	Microbiome-based therapeutics: what we know so far
10.20-10.40	Q&A
10.40-11.00	<i>Coffe break</i>

Session 4_____Promising pathways and strategies in GI tumors

11.00-11:20	Recent advances for bispecific Abs in gastroesophageal cancer
11.20-11.40	PARP (and beyond)-mediated syntethic lethality in pancreatic cancer
11.40-12.00	Precision medicine with TKIs in GIST: the role of pharmacogenetics
12.00-12.20	What's new in GEP-NET
12.20-12.40	Q&A
12.40-13.40	<i>Light lunch</i>

Session 5_____Re-thinking surgical approach in GI oncology

13.40-14.00	Curative surgery in oligometastatic gastric cancer: where are we?
14.00-14.20	Non operative management in MSI tumors
14.20-14.40	HIPEC, PIPAC, and intraperitoneal infusion in colorectal and gastric tumors: let's take stock
14.40-15.00	Liver transplant in CRLM and liver primary tumors: what oncologist need to know
15.00-15.20	Q&A

Session 6_____Controversies in GI oncology

15.20-15.40	Chemoradiotherapy for esophageal adenocarcinoma: still a place?
15.40-16.00	The optimal neoadjuvant strategy for resectable/borderline resectable pancreatic cancer
16.00-16.20	Second and beyond lines in MSI colorectal cancer: practical aspects and clinical studies
16.20-16.40	The best choice for first line therapy in HCC: any useful algorithm?
16.40-17.00	Q&A and closing remarks

11th ESDO MASTERCLASS

Novel Strategies in GI Oncology



19-20
NOVEMBER 2027



VENICE



VENUE SCUOLA GRANDE SAN MARCO VENICE

An iconic historical venue in the heart of Venice,
where tradition meets innovation.



ORGANIZING SECRETARIAT
MEETING SRL



info@meetingsrl.eu



+39 0432 1790500



www.meetingsrl.eu

m. | meeting.